Application of Desferal to Treat COVID-19
Sponsor
Kermanshah University of Medical Sciences (Other)
Overall Status
Unknown status
CT.gov ID
NCT04333550
Collaborator
(none)
50
1
2
11
4.6
Study Details
Study Description
Brief Summary
In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations
Anticipated Study Start Date
:
Apr 1, 2020
Anticipated Primary Completion Date
:
Sep 1, 2020
Anticipated Study Completion Date
:
Mar 1, 2021
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental: Desferal addition to standard treatment
|
Drug: Deferoxamine
Intravenous infusion of Deferoxamine
|
| Experimental: Experimental: standard treatment
|
Drug: Deferoxamine
Intravenous infusion of Deferoxamine
|
Outcome Measures
Primary Outcome Measures
- Mortality rate [up to 20 days]
All cause of death
Secondary Outcome Measures
- change in patients clinical manifestation [up to 20 days]
Mild, Moderate or Severe
- change in patients PaO2 [up to 20 days]
- Length of hospitalization [up to 20 days]
days
- C-reactive protein [up to 20 days]
- lymphocyte count [up to 20 days]
- length of intensive care unit stay [1 to 20 days]
Eligibility Criteria
Criteria
Ages Eligible for Study:
3 Years
to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Clinical diagnosis of COVID-19 Disease,
Exclusion Criteria:
Previous history of allergy to Deferoxamin, Pregnancy, kidney dysfunction,
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran | Kermanshah | Iran, Islamic Republic of | 083 |
Sponsors and Collaborators
- Kermanshah University of Medical Sciences
Investigators
- Study Director: Yadollah Shakiba, MD, PhD, Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
- Principal Investigator: Amir Kiani, PhD, Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Dr. Yadollah Shakiba,
Dr. Yadollah Shakiba, MD, PhD,
Kermanshah University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT04333550
Other Study ID Numbers:
- 1398.1224
First Posted:
Apr 3, 2020
Last Update Posted:
May 4, 2020
Last Verified:
Apr 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr. Yadollah Shakiba,
Dr. Yadollah Shakiba, MD, PhD,
Kermanshah University of Medical Sciences
Additional relevant MeSH terms: